[go: up one dir, main page]

PE20001384A1 - Derivados de acetamida no peptidicos como antagonistas de receptor de nk1 - Google Patents

Derivados de acetamida no peptidicos como antagonistas de receptor de nk1

Info

Publication number
PE20001384A1
PE20001384A1 PE1999001281A PE00128199A PE20001384A1 PE 20001384 A1 PE20001384 A1 PE 20001384A1 PE 1999001281 A PE1999001281 A PE 1999001281A PE 00128199 A PE00128199 A PE 00128199A PE 20001384 A1 PE20001384 A1 PE 20001384A1
Authority
PE
Peru
Prior art keywords
alkyl
peptidic
receptor antagonists
thenyl
propionamide
Prior art date
Application number
PE1999001281A
Other languages
English (en)
Inventor
David Christopher Horwell
Mark Wallace Creswell
Michael Higginbottom
Russell Andrew Lewthwaite
Martyn Clive Pritchard
Jennifer Raphy
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20001384A1 publication Critical patent/PE20001384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTOS DERIVADOS DE ACETAMIDA NO PEPTIDICOS DE FORMULA I, DONDE R ES PIRIDILO, TIENILO, FURILO, PIRROLILO, PIRAZOLILO, QUINOLINILO, ISOQUINOLILO, NAFTILO, ENTRE OTROS; O R1 Y R2 SON H, ALQUILO C1-C4; m ES 0-3; X ES NHCONH, NR8; R8 ES H, ALQUILO C1-C4; R3 ES H, ALQUILO C1-C4; n ES 1-2; R4 ES NAFTILO, INDOLILO; R9 ES H, ALQUILO C1-C4; R5 Y R7 SON H, (CH2)pR10; p ES 1-3; R10 ES H, CH3, CN, OH, OCH3, CO2CH3, NH2, NHCH3, N(CH3)2; q ES 0-4; R6 ES FENILO, PIRIDILO, TIENILO, FURILO, PIRROLILO, ALQUILO C1-C3, CICLOALQUILO C5-C8, ENTRE OTROS; CUANDO R5 Y R6 ESTAN UNIDOS POR UN ENLACE FORMAN UN ANILLO. SON COMPUESTOS PREFERIDOS 2-[(BENZOFURAN-2-ILMETIL)-AMINO]-3-(1H-INDOL-3-IL)-2-METIL-N-(1-FENIL-ETIL)PROPIONAMIDA, [R-(R*,S*)]; 2-[(BENZOFURAN-2-ILMETIL)AMINO]-3-(1H-INDOL-3-IL)-2-METIL-N-(1-PIRIDIN-4-IL-ETIL)-PROPIONAMIDA, [R-(R*,S*)], ENTRE OTROS. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR NEUROQUININA NK1, POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE UN TRASTORNO DEL SNC, COMO DOLOR, ANSIEDAD, DEPRESION, ESQUIZOFRENIA, NEURALGIA, STRESS, TRASTORNO ALERGICO O INFLAMATORIO
PE1999001281A 1998-12-18 1999-12-17 Derivados de acetamida no peptidicos como antagonistas de receptor de nk1 PE20001384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11272598P 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
PE20001384A1 true PE20001384A1 (es) 2000-12-30

Family

ID=22345539

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001281A PE20001384A1 (es) 1998-12-18 1999-12-17 Derivados de acetamida no peptidicos como antagonistas de receptor de nk1

Country Status (9)

Country Link
US (2) US6472418B1 (es)
EP (1) EP1140914A1 (es)
JP (1) JP2002533338A (es)
AU (1) AU2180600A (es)
CA (1) CA2355137A1 (es)
CO (1) CO5170508A1 (es)
PE (1) PE20001384A1 (es)
UY (1) UY25864A1 (es)
WO (1) WO2000037462A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
CN1413206A (zh) * 1999-12-22 2003-04-23 沃尼尔·朗伯公司 非肽类速激肽受体拮抗剂
GB2369118A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
HUP0303500A2 (hu) * 2000-11-17 2004-01-28 Warner-Lambert Company Llc Eljárás szexuális rendellenességek kezelésére bombezin-antagonisták segítségével
EP1333824B1 (en) * 2000-11-17 2005-09-07 Warner-Lambert Company LLC Treatment of sexual dysfunction with bombesin receptor antagonists
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP3470402B1 (en) 2009-11-12 2021-01-06 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2014052659A1 (en) 2012-09-27 2014-04-03 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP2021509398A (ja) 2017-08-21 2021-03-25 プレックス ファーマスーティカルズ，インク 二重作用ｆｋｂｐ１２およびｆｋｂｐ５２阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DK0655055T3 (da) 1992-08-13 2001-01-02 Warner Lambert Co Tachykininantagonister
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
JPH10501228A (ja) * 1994-06-06 1998-02-03 ワーナー−ランバート・コンパニー タキキニン（ｎｋ▲下１▼）受容体アンタゴニスト
EP0920424B1 (en) 1996-08-22 2005-11-30 Warner-Lambert Company Llc Non-peptide bombesin receptor antagonists
JP2002511467A (ja) 1998-04-15 2002-04-16 ワーナー−ランバート・カンパニー ベンゾフラニルメチルカルバメートｎｋ１拮抗物質のプロドラッグ

Also Published As

Publication number Publication date
WO2000037462A1 (en) 2000-06-29
AU2180600A (en) 2000-07-12
CA2355137A1 (en) 2000-06-29
CO5170508A1 (es) 2002-06-27
EP1140914A1 (en) 2001-10-10
US6472418B1 (en) 2002-10-29
US20030065007A1 (en) 2003-04-03
JP2002533338A (ja) 2002-10-08
UY25864A1 (es) 2001-08-27

Similar Documents

Publication Publication Date Title
PE20001384A1 (es) Derivados de acetamida no peptidicos como antagonistas de receptor de nk1
NO2005023I1 (no) Palonosetron HCI
DK191186A (da) Indolderivater
PE106499A1 (es) Antagonistas del receptor ccr-3
LV11035A (lv) Jauni benzimidazolin-2-okso-1-karbonskabes atvasinajumi kuri pielietojami ka serotonina (5-HT) receptoru antagonisti
UA84022C2 (ru) Производные (тио)карбамоилциклогексана как антагонисты d3/d2 рецептора
CA2318579A1 (en) Nitrogen-containing heterocyclic compounds and medicaments containing the compounds
PE20011035A1 (es) Ureas ciclicas sustituidas como antagonistas de los receptores de neuroquinina
FR2673427B1 (fr) Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
DK0858461T3 (da) Kondenserede tropanderivater som neurotransmittergenoptagelsesinhibitorer
ATE128463T1 (de) Piperidin und pyrrolidin derivate.
DK1054885T3 (da) Benzisoxasolderivater med D4-antagonistisk virkning
PE51499A1 (es) Derivados de 5-aroilnaftaleno
KR950702978A (ko) 아미드 유도체(Amide derivatives)
TR22719A (tr) Yeni n-alkil(en)-n-(o,o-disuebstuee-tiofos foril)-n',n'-disuebstituee glisin amidler bunlari hazirlamaya mahsus usuel ve etkili terkip maddesi olarak bu bilesikleri ihtiva eden akarisid ensektisid ve fungisid
ES8403899A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.
ECSP993082A (es) Compuestos monociclicos con accion antagonista nk2 y composicion que los contienen

Legal Events

Date Code Title Description
FC Refusal